March 05, 2014
1 min read

Santen, Tracon to develop anti-endoglin antibodies in ophthalmology

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Santen Pharmaceutical Co. has entered into an exclusive agreement with Tracon Pharmaceuticals for the development and global commercialization of Tracon’s anti-endoglin antibodies, including TRC105, in ophthalmology, according to a press release.

TRC105 in combination with anti-VEGF products, as preclinical and clinical data have shown in oncology, has the potential to be a more effective treatment for conditions such as wet age-related macular degeneration than inhibiting VEGF alone, the release said.

Under the agreement, Santen will make a $10 million upfront payment to Tracon, as well as certain milestone payments throughout the development phase. Santen will also pay commercialization milestones and tiered royalties on global sales of TRC105 in ophthalmology, according to the release.